<DOC>
	<DOCNO>NCT01509937</DOCNO>
	<brief_summary>It hypothesize bioimpedance spectroscope guide fluid management help patient reach euvolemic status , increase long term survival . Background : Bioimpedance analysis ( BIA ) helpful identify hypervolemia . Observational data use BIA method show hypervolemic patient maintenance hemodialysis ( MHD ) suffer high mortality risk . But clear BIA guide fluid management improve MHD patient ' survival . The objective BOCOMO study evaluate outcome BIA guide fluid management compare standard care . Design : This multicenter , prospective , randomize , control trial . Setting Participants : More 1300 participant 16 clinical site include study . The enrollment period last 6 month , minimum length follow-up le 36 month . MHD patient age 18 year less 80 year MHD least 3 month consider suitable candidate invite participate study . Participants randomize BIA arm control arm use 1:1 ratio . A portable whole body bioimpedance spectroscopy device ( BCMâ€”Fresenius Medical Care D GmbH ) use BIA measurement baseline arm , every 2 month BCM arm . Predictors : BCM guide fluid management fluid management use standard care . Outcome measurement : The primary intent-to-treat analysis compare composite endpoint BCM arm control arm . The secondary intent-to-treat analysis compare leave ventricular thickness , blood pressure , medication , incidence length hospitalization BCM arm control arm . Death , acute myocardial infarction , stroke , peripheral arterial disease use composite endpoint .</brief_summary>
	<brief_title>Body Composition Monitor ( BCM ) Guided Fluid Management Maintenance Hemodialysis ( MHD ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>diagnosis end stage renal disease ( ESRD ) need MHD age 18 year old 80 year less MHD least 3 month dialysis frequency least 5 session per 2 week , le 4 hour per session , Kt/V least 1.2 urine volume le 800mL per 24 hour day dialysis session , bioimpedance analysis use within recent 3 month dry weight regard adequate accord patient 's responsible doctor ability understand willingness sign inform consent statement . acute infection within 1 month active rheumatic disease , current cortical steroid medication cytotoxic medication uncontrolled neoplasm acute myocardial infarction within 1 month congestive heart failure ( NYHA 3 4 ) stroke within 3 month , metallic installation , like contraceptive device , artificial joint ( ) amputation female childbearing age pregnancy plan , pregnant , breast feeding plan reduce dialysis frequency renal transplantation plan plan transfer peritoneal dialysis within 3 year participate planning participate another clinical trial , confound current study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>end stage renal disease</keyword>
	<keyword>maintenance hemodialysis</keyword>
	<keyword>dry weight</keyword>
	<keyword>bioimpedance spectroscopy analysis</keyword>
	<keyword>body composition monitor</keyword>
	<keyword>Fresenius BCM</keyword>
	<keyword>Ultrafiltration</keyword>
</DOC>